Alnylam Pharma is said to be a potential target for Novartis - Bloomberg
Nov. 18, 2021 7:19 AM ETAlnylam Pharmaceuticals, Inc. (ALNY)NVS, NVO, REGN, NTLABy: Joshua Fineman, SA News Editor10 Comments
JHVEPhoto/iStock Editorial via Getty Images
- Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis (NYSE:NVS) as investor push for the drugmaker to make an acquisition and use its cash. Alnylam rose 4.2% in premarket trading.
- Alnylam, with a market cap of more than $20B could be a possible acquisition candidate, according to a Bloomberg report, which cited people familiar.
- Novartis declined to comment to Bloomberg on potential acquisitions.
- Alnylam (ALNY) was likely also on the the mover after Novo Nordisk (NYSE:NVO) agreed to acquire Dicerna (NASDAQ:DRNA) for more than $3B. ALNY is focused on RNAi therapies, similar to Dicerna.
- Earlier this month, Intellia Therapeutics, Alnylam seen as potential Regeneron (NASDAQ:REGN) targets, analyst says. Benchmark analyst Aydin Huseynov wrote that ALNY would likely be worth more than $30B in an acquisition.
Recommended For You
Comments (10)
Have a tip? Submit confidentially to our News team. Found a factual error? Report here.
k
knowsstox
18 Nov. 2021
ALNY has rapidly growing revenues, a great RNAi platform for drug development and great data on a potentially game changing therapy for hypertension. Plus NVS will save billions by not having to pay inclisiran royalties to ALNY. Impending buyout may explain Alnylam CEOโs John Maraganore surprising retirement plans. I sense there may be something to this.
r
rudyel
18 Nov. 2021
haa haa just another rumor and bust!
d
dom_biotech
18 Nov. 2021
@rudyel ๐๐๐
c
chrloe
18 Nov. 2021
If Novartis were economically savvy they'd go for VRTX instead. Next year's economic bust will be all about having US dollars or not. Not much use adding an EPS negative company to their assets.

stevevai1983
18 Nov. 2021
@chrloe VRTX is too expensive for a buy out. You must prepare something like 70B.
k
knowsstox
18 Nov. 2021
@stevevai1983 your math is way way way way off. $70 billion would be around $600 per share. Nobody is talking anything in that price range.
k
knowsstox
18 Nov. 2021
@stevevai1983 sorry, thought you were talking about ALNY.
s
settembrini007
18 Nov. 2021
ALNY would be another bad acquisition for Novartis. Translation: they might actually do it to fail again.
P
Pharma95410
18 Nov. 2021
@settembrini007 Bad because they have best in class platform technology? Or because every drug they try and launch smashes clinical expectations?